The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.

Seattle Genetics and development partner Takeda Pharmaceutical announced stellar Phase III data from the ECHELON-2 clinical trial of Adcetris (brentuximab vedotin) for peripheral T-cell lymphoma.

Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.

Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.

Merck & Co. halted two Phase III multiple myeloma trials testing the company’s blockbuster anti-PD-1 drug Keytruda after an external monitoring committee expressed concern over trial patient deaths in the groups taking the drug.

The European Commission approved Merck’s anti-PD-1 therapy Keytruda for treating adult patients with relapsed or refractory classical Hodgkin lymphoma.

Merck & Co. Inc. said it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.